Cancer burden in Africa and opportunities for prevention.

Surveillance Research Program, American Cancer Society, Atlanta, Georgia. .
Cancer (Impact Factor: 5.2). 01/2012; 118(18):4372-84. DOI: 10.1002/cncr.27410
Source: PubMed

ABSTRACT Cancer is an emerging public health problem in Africa. About 715,000 new cancer cases and 542,000 cancer deaths occurred in 2008 on the continent, with these numbers expected to double in the next 20 years simply because of the aging and growth of the population. Furthermore, cancers such as lung, female breast, and prostate cancers are diagnosed at much higher frequencies than in the past because of changes in lifestyle factors and detection practices associated with urbanization and economic development. Breast cancer in women and prostate cancer in men have now become the most commonly diagnosed cancers in many Sub-Saharan African countries, replacing cervical and liver cancers. In most African countries, cancer control programs and the provision of early detection and treatment services are limited despite this increasing burden. This paper reviews the current patterns of cancer in Africa and the opportunities for reducing the burden through the application of resource level interventions, including implementation of vaccinations for liver and cervical cancers, tobacco control policies for smoking-related cancers, and low-tech early detection methods for cervical cancer, as well as pain relief at the palliative stage of cancer. Cancer 2012. © 2012 American Cancer Society.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to analyze the expression, clinical significance of stanniocalcin 2 in cervical carcinoma patients who were treated with radiotherapy. Stanniocalcin 2 expression was determined by real-time PCR in 10 pairs of cervical cancer and adjacent normal cervical tissues. Tumor samples from 92 patients diagnosed from 2004 to 2007 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be cervical carcinoma without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. The samples were immunohistochemically analyzed for stanniocalcin 2 expression and survival analyses were performed. The tumors of cervical cancer patients had significantly increased expression of stanniocalcin 2 at mRNA level compared with adjacent normal cervical tissues. High levels of stanniocalcin 2 expression was correlated with shorter overall survival, whereas low levels of stanniocalcin 2 expression was correlated with longer overall survival (P = 0.003) and progression free survival (P = 0.001) after radiotherapy. Moreover, high expression of stanniocalcin 2 was correlated with lymph node metastasis (P = 0.002). Stanniocalcin 2 could be a useful marker for the prognosis of cervical cancer patients receiving radiotherapy. Stanniocalcin 2 may contribute to tumor development and radioresistance in cervical cancer.
    International journal of clinical and experimental pathology 01/2014; 7(12):8770-6. · 1.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the clinical significance of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in cervical cancer. We examined ROR2 levels in 8 pairs of surgically resected cervical cancer and adjacent normal cervical tissues by real-time PCR. Moreover, we performed immunohistochemistry to examine ROR2 expression in 94 paraffin-embedded cervical cancer samples and analyzed the association between ROR2 expression, clinicopathologic factors and prognosis. ROR2 expression was up-regulated in cervical cancer tissues compared with adjacent normal cervix. In paraffin-embedded cervical cancer samples, high expression of ROR2 was shown in 40 (42.6%) of 94 cases, also, it was significantly associated with tumor stage (P = 0.018) and lymph nodes metastasis (P = 0.013). Moreover, survival analysis showed that ROR2 expression was an independent prognostic factor of poor overall and recurrent free survival (P = 0.045 and 0.001, respectively). These results indicate that ROR2 is significantly correlated with cancer progression and poor prognosis in cervical cancer.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-communicable diseases (NCDs) result in more deaths globally than other causes. Monitoring systems require strengthening to attribute the NCD burden and deaths in low and middle-income countries (LMICs). Data from health and demographic surveillance systems (HDSS) can contribute towards this goal. Between 2003 and 2010, 15,228 deaths in adults aged 15 years (y) and older were identified retrospectively using the HDSS census and verbal autopsy in rural western Kenya, attributed into broad categories using InterVA-4 computer algorithms; 37% were ascribed to NCDs, 60% to communicable diseases (CDs), 3% to injuries, and <1% maternal causes. Median age at death for NCDs was 66y and 71y for females and males, respectively, with 43% (39% male, 48% female) of NCD deaths occurring prematurely among adults aged below 65y. NCD deaths were mainly attributed to cancers (35%) and cardio-vascular diseases (CVDs; 29%). The proportionate mortality from NCDs rose from 35% in 2003 to 45% in 2010 (χ2 linear trend 93.4; p<0.001). While overall annual mortality rates (MRs) for NCDs fell, cancer-specific MRs rose from 200 to 262 per 100,000 population, mainly due to increasing deaths in adults aged 65y and older, and to respiratory neoplasms in all age groups. The substantial fall in CD MRs resulted in similar MRs for CDs and NCDs among all adult females by 2010. NCD MRs for adults aged 15y to <65y fell from 409 to 183 per 100,000 among females and from 517 to 283 per 100,000 population among males. NCD MRs were higher among males than females aged both below, and at or above, 65y. NCDs constitute a significant proportion of deaths in rural western Kenya. Evidence of the increasing contribution of NCDs to overall mortality supports international recommendations to introduce or enhance prevention, screening, diagnosis and treatment programmes in LMICs.
    PLoS ONE 11/2014; 9(11):e114010. DOI:10.1371/journal.pone.0114010 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Oct 22, 2014